论文部分内容阅读
目的:探讨胸腺肽α1对小儿重症肺炎肿瘤坏死因子及白细胞介素-6的影响。方法:选择2012年7月—2014年10月在妇幼保健院儿科接受治疗的重症肺炎患儿86例作为研究对象,86例重症肺炎患儿随机分成对照组和观察组两组,各43例。对照组患者接受重症肺炎的常规药物治疗。观察组在对照组治疗的基础上同时皮下注射胸腺肽α1。结果:观察组重症肺炎患儿的总有效率为95.35%高于对照组重症肺炎患儿的总有效率79.07%,差异具有统计学意义(χ2=5.108,P<0.05)。治疗后,观察组患儿的m HLA-DR水平(46.2±8.5)%高于对照组患儿的m HLA-DR水平(33.1%±3.5%,且观察组患儿IL-6水平(44.6±11.3)ng·L-1、TNF-α水平(42.4±11.7)ng·L-1低于对照组患儿的IL-6水平(67.1±22.5)ng·L-1、TNF-α水平(63.2±21.1)ng·L-1,差异具有统计学意义(P<0.01)。治疗后,观察组患儿CD3+水平(55.2±9.6)%、CD4+水平(53.4±9.9)%、CD4+/CD8+水平(2.5±1.2)%高于对照组患儿的CD3+水平(44.8±9.1)%、CD4+水平(42.5±9.5)%、CD4+/CD8+水平(1.7±0.8)%,且观察组患儿CD8+水平(24.6±3.1)%低于对照组患儿CD4+/CD8+水平(33.7±4.2)%,差异具有统计学意义(P<0.01)。治疗后,观察组患儿的MMF水平(1.72±0.29)L/s、PEF水平(2.14±0.28)L/s、PImax水平(83.41±8.23)%及PEmax水平(47.81±6.16)%高于对照组患儿的MMF水平(1.16±0.24)L/s、PEF水平(1.48±0.27)L/s、PImax水平(73.93±7.44)%及PEmax水平(39.23±5.76)%,差异具有统计学意义(P<0.01)。结论:胸腺肽α1治疗小儿重症肺炎能够减轻患儿局部炎症反应、提高免疫功能、改善肺功能,进而增强治疗效果。
Objective: To investigate the effect of thymosin α1 on tumor necrosis factor and interleukin-6 in children with severe pneumonia. Methods: Totally 86 children with severe pneumonia treated in pediatric department of MCH from July 2012 to October 2014 were enrolled in this study. Totally 86 children with severe pneumonia were randomly divided into control group and observation group, 43 cases in each group. Patients in the control group received routine medical treatment of severe pneumonia. Observation group in the control group on the basis of the same time, subcutaneous injection of thymosin α1. Results: The total effective rate of children with severe pneumonia in the observation group was 95.35%, which was significantly higher than that in the control group (79.07%, severe pneumonia). The difference was statistically significant (χ2 = 5.108, P <0.05). After treatment, the level of m HLA-DR in observation group (46.2 ± 8.5%) was higher than that in control group (33.1% ± 3.5%, IL-6 level in observation group (44.6 ± 11.3) ng · L-1, and the level of TNF-α (42.4 ± 11.7 ng · L-1) was lower than that of the control group (67.1 ± 22.5 ng · L-1) ± 21.1 ng · L-1, the difference was statistically significant (P <0.01) .After treatment, the level of CD3 + in the observation group was 55.2 ± 9.6%, the level of CD4 + was 53.4 ± 9.9% and the level of CD4 + / CD8 + 2.5 ± 1.2)% was higher than that of control group (44.8 ± 9.1%), CD4 + (42.5 ± 9.5)%, CD4 + / CD8 + (1.7 ± 0.8)%, and CD8 + ± 3.1)% was lower than that of the control group (33.7 ± 4.2)%, the difference was statistically significant (P <0.01) .After treatment, the level of MMF in the observation group was (1.72 ± 0.29) L / s , The PEF level (2.14 ± 0.28) L / s, the PImax level (83.41 ± 8.23)% and the PEmax level (47.81 ± 6.16)% were higher than those in the control group (1.16 ± 0.24) L / 1.48 ± 0.27) L / s, PImax level (73.93 ± 7.44)% and PEmax level (39.23 ± 5.76)%, the difference was statistically significant (P0.01) .Conclusion: Thymosin α1 can reduce severe pneumonia in children Children with local inflammation, improve immune function, improved pulmonary function, and thus enhance the therapeutic effect.